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Abstract 
Review on Renal cell carcinoma with 
t(X;17)(p11;q23) CLTC/TFE3, with data on clinics, 
and the genes involved. 
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Identity 
Other names 
Renal cell carcinoma with CLTC-TFE3 gene fusion 
Classification 
This renal cell carcinoma, of which there is only a 
single reported case, belongs to the family of Xp11 
translocation renal carcinomas. Xp11 translocation 
renal cell carcinoma (RCCs) harbor gene fusions 
involving TFE3 transcription factor.   
The t(6;11) RCCs harbor a specific MALAT1 
(Alpha) - TFEB gene fusion.   
TFEB and TFE3 belong to the same MiT subfamily 
of transcription factors.  
Because of similarities at the clinical, morphologic, 
immunohistochemical, and genetic levels, the Xp11 
translocation RCCs and t(6;11) RCCs are currently 
grouped together under the category of  MiT family 
translocation renal cell carcinoma. 
Clinics and pathology 
Etiology 
Unclear. 
Epidemiology 
Single case report in a 14 year old male. 
Pathology 
The tumor was bounded by a calcified fibrous 
pseudocapsule. The tumor had predominantly a 
solid, compact nested pattern, as islands of tumor 
cells were demarcated by fibrovascular septa. More 
dyscohesive areas yielded a papillary architecture. 
Focal calcifications, some in the form of 
psammoma bodies, were frequent, often associated 
with hyaline nodules. Tumor cells were polygonal 
with well-demarcated, predominantly clear, 
voluminous cytoplasm. However, there were 
scattered areas in which the cells were smaller and 
others where they demonstrated densely 
eosinophilic cytoplasm; the latter areas had a nested 
growth pattern and foci of central necrosis, 
somewhat reminiscent of hepatocellular carcinoma. 
Mitoses were sparse. 
Immunohistochemical (IHC) analysis showed 
strong and diffuse nuclear labeling with a 
polyclonal antibody to the TFE3 C-terminal 
portion, as seen in other tumors associated with 
TFE3 gene fusions.  
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Since native TFE3 protein is not detectable in non-
neoplastic cells by the same assay, this finding is 
consistent with constitutive expression of a nuclear 
fusion protein containing the TFE3 C-terminal 
portion, such as the predicted CLTC-TFE3 protein. 
Like most conventional (clear cell) and papillary 
RCCs, the tumor contained tumor cells were 
strongly and diffusely immunoreactive for CD10, 
showing strong cytoplasmic staining with 
membranous accentuation. However, unlike most 
typical adult RCCs, IHC with all cytokeratin 
antibodies (Cam5.2, AE1/3, Cytokeratin 7) and the 
"RCC" monoclonal antibody yielded negative 
reactions, though tumor cells did label in one 
isolated area for Epithelial Membrane Antigen 
(EMA).  
Underexpression of common epithelial proteins is a 
typical feature of Xp11.2-translocation carcinomas. 
Surprisingly, the tumor was focally immunoreactive 
for the melanocytic proteins Melan-A and HMB45 
but IHC assays for MiTF and S100 protein were 
negative. While unusual, the immunoreactivity for 
melanocytic markers can be seen in Xp11 
translocation carcinomas. 
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Treatment 
Nephrectomy. 
Prognosis 
Unclear. 
Genes involved and 
proteins 
Note 
The t(X;17)(p11.2;q23) results in a CLTC/TFE3 
gene fusion. 
TFE3 (transcription factor E3) 
Location Xp11.23 
DNA / RNA 
The TFE3 gene includes a 5¹ untranslated region, 8 
exons, and a 3¹ untranslated region. 
Protein 
TFE3 is a transcription factor with a basic helix-
loop-helix DNA binding domain and a leucine 
zipper dimerization domain. TFE3 contains a 
nuclear localization signal, encoded at the junction 
of exons 5 and 6, which is retained within all 
known TFE3 fusion proteins. TFE3 protein is 575 
amino acids, and is ubiquitously expressed. 
TFE3, TFEB, TFEC and Mitf comprise the 
members of the microphthalmia transcription factor 
subfamily, which have homologous DNA binding 
domains and can bind to a common DNA sequence. 
These four transcription factors may homo- or 
heterodimerize to bind DNA, and they may have 
functional overlap. 
CLTC (clathrin heavy polypeptide) 
Location 17q23.1 
Note 
Clathrin is the major protein constituent of the coat 
that surrounds organelles (cytoplasmic vesicles) to 
mediate selective protein transport. Clathrin coats 
are involved in receptor-mediated endocytosis and 
intracellular trafficking and recycling of receptors, 
which accounts for its characteristic punctate  
cytoplasmic and perinuclear cellular distribution. 
Structurally, clathrin is a triskelion (three-legged) 
shaped protein complex that is composed of a 
trimer of heavy chains (CLTC) each bound to a 
single light chain. CLTC is a 1675 amino acid 
residue protein encoded by a gene consisting of 32 
exons. Its known domains include a N-terminal 
globular domain (residues 1-494) that interacts with 
adaptor proteins (AP-1, AP-2, b-arrestin), a light 
chain-binding region (residues 1074-1552), and a 
trimerization domain (residues 1550-1600) near the 
C-terminus. 
Result of the chromosomal 
anomaly 
Fusion Protein 
Description 
In the CLTC-TFE3 fusion, the fusion point on 
CLTC is at amino acid 932 (corresponding to the 
end of exon 17), thereby excluding the CLTC 
trimerization domain from the predicted fusion 
protein. As in other TFE3 gene fusions, the nuclear 
localization and DNA binding domains of TFE3 are 
retained in CLTC-TFE3. Based on these features 
and existing data on other TFE3 fusion proteins, 
CLTC-TFE3 may act as an aberrant transcription 
factor, with the CLTC promoter driving constitutive 
expression. 
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